Neurogene Inc. (NGNE)
- Previous Close
15.22 - Open
15.33 - Bid 13.75 x 200
- Ask 23.64 x 200
- Day's Range
14.85 - 19.51 - 52 Week Range
6.88 - 74.49 - Volume
510,220 - Avg. Volume
269,556 - Market Cap (intraday)
276.257M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.36 - Earnings Date Aug 7, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
40.60
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
www.neurogene.comRecent News: NGNE
View More
Performance Overview: NGNE
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NGNE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NGNE
View MoreValuation Measures
Market Cap
276.68M
Enterprise Value
-2.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
389.89
Price/Book (mrq)
0.95
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.97%
Return on Equity (ttm)
-34.96%
Revenue (ttm)
925k
Net Income Avi to Common (ttm)
-80.87M
Diluted EPS (ttm)
-4.36
Balance Sheet and Cash Flow
Total Cash (mrq)
292.6M
Total Debt/Equity (mrq)
4.01%
Levered Free Cash Flow (ttm)
-40.39M